Physician profile
Madison Lowry
NPI 1639129265
$4,774.33
in general payments reported to CMS, 2019-2025
32 companies · $1,315 in 2025
The $1,315 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $78.67 · 2021: $326 · 2022: $609 · 2023: $1,237 · 2024: $795 · 2025: $1,315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,346.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $722.94 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $512.16 | 2022-2025 | Mounjaro, Jardiance |
| Amgen INC. | $424.42 | 2023-2025 | Tavneos, Otezla, Repatha |
| Abbott Laboratories | $309.94 | 2022-2023 | Octrode, Freestyle Libre 2 |
| Amarin Pharma, INC. | $274.96 | 2019 | |
| Medtronic, INC. | $265.00 | 2021-2025 | Inceptiv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.87 | 2025 | Caplyta |
| Mannkind Corporation | $162.06 | 2019-2023 | Afrezza |
| Si-Bone, INC. | $161.32 | 2025 | |
| Corium, LLC | $134.60 | 2022-2023 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $131.40 | 2023 | |
| Alfasigma USA, INC. | $130.65 | 2021 | |
| Abbvie INC. | $121.71 | 2025 | |
| Alexion Pharmaceuticals, INC. | $116.24 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.42 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $110.45 | 2023-2024 | Capvaxive, Vaxneuvance |
| Idorsia Pharmaceuticals US INC | $109.78 | 2023 | Quviviq |
| Cardiovascular Systems INC. | $103.62 | 2019 | |
| Organogenesis INC. | $101.19 | 2023 | Puraply |
| Pfizer INC. | $91.36 | 2024-2025 | |
| Madrigal Pharmaceuticals | $88.84 | 2025 | Rezdiffra |
| Otsuka America Pharmaceutical, INC. | $85.34 | 2022-2023 | Rexulti |
| Procept Biorobotics Corporation | $69.04 | 2025 | |
| Inspire Medical Systems, INC. | $61.71 | 2024 | Inspire |
| Organon LLC | $44.16 | 2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $30.18 | 2024 | |
| Dermira, INC. | $17.99 | 2020 | |
| Currax Pharmaceuticals LLC | $17.27 | 2024 | Contrave |
| Sanofi Pasteur INC. | $15.32 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $12.09 | 2020 | |
| Cranial Technologies, INC | $12.07 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.